Millions of middle-aged people should be prescribed weight-loss injections to cut their risk of heart attacks and strokes by a fifth, according to a trial set to revolutionise medical practice.

The largest study yet carried out into semaglutide – also known as Ozempic or Wegovy – has found that the drug cuts heart disease deaths by about 20 per cent, potentially even if people do not lose weight.

Walter & Eliza Hall Institute Endocrinologist Associate Professor John Wentworth told Millsy and Karl there’s potential with the massively popular drug, yet lack of data and prohibitive costs mean we have to be careful.

Press PLAY to hear the full story